Tilray Brands Inc vs Verisign, Inc. — how do they compare? Tilray Brands Inc trades at $3.53 (market cap $530.54M), while Verisign, Inc. trades at $304.9 (market cap $26.92B). The key difference: Verisign, Inc. is far larger — about 50.7× Tilray Brands Inc's market cap, and Verisign, Inc. pays a 1.09% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tilray Brands Inc for 31 Days and Verisign, Inc. for 123 Days on average.
| TLRY | VRSN | |
|---|---|---|
Market Cap | $530.54M | $26.92B |
Volume | 9,099,075 | 1,921,402 |
Sector | Health | Technology |
52-Week High | $21.00 | $310.00 |
52-Week Low | $3.57 | $211.49 |
Typical Hold Time | 31 Days | 123 Days |
Enterprise Value | $684.46M | $28.23B |
Dividend Yield | — | 1.09% |
Signals from Pluang's Aura AI — not financial advice
Tilray Brands (TLRY) trades at $3.50, down 5.79% on the day and near its 52-week low. The stock shows bearish technical signals with negative moving averages and recent earnings misses across four consecutive quarters. Despite revenue growth to $821 million in 2025, the company reported a substantial net loss of $2.19 billion, driven by impairment charges and high operating costs. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $65.01 suggests significant potential upside from current levels.
The outlook remains challenging with persistent profitability issues and negative cash flow from operations. Investment opportunity exists if Tilray can achieve projected 2026 revenue growth to $915 million and reduce losses. Key risks include ongoing operational inefficiencies, competitive pressures in the cannabis market, and regulatory uncertainty. The stock's current valuation at 0.44 P/S and 0.33 P/B may attract value investors betting on a turnaround.
VeriSign (VRSN) trades at $305.53, up 3.84% today, with a bullish technical outlook and strong institutional buying. The company reported solid Q2 2026 results with revenue up 6% year-over-year and EPS of $2.38, though it missed expectations slightly. High profitability is evident with a net income margin near 50%, but valuation multiples like P/E of 32.33 are elevated. Recent news includes an antitrust lawsuit and insider selling by the CEO, while major institutions like BlackRock have increased stakes.
The stock offers growth potential from domain registration increases and AI-driven demand, with a consensus price target of $348 implying 14% upside. Risks include regulatory scrutiny from the antitrust case, high debt levels, and premium valuation. Analyst sentiment is positive with 60% buy ratings, but investors should monitor Q3 2026 earnings on October 22 for confirmation of growth trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →